← Eichor
Condition: Immunogenicity Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Immunogenicity

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of B-3E07 and Forsteo® in Healthy Adult Female Participants
Phase 1 · 1 location(s) · Syneos Health · NCT07497503A Clinical Trial Evaluating the Monkeypox Recombinant Protein Vaccine
Phase 1 · 1 location(s) · Shanghai JunTop Biosciences Co., LTD · NCT07495202A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)
Phase 1/Phase 2 · 4 location(s) · Latticon Antibody Therapeutics, Inc · NCT06277219Shingrix In Recipients of Allogeneic Transplants
Phase 2 · 1 location(s) · University of Colorado, Denver · NCT05775718Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa
Phase 2 · 1 location(s) · Sinocelltech Ltd. · NCT07244510Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i
Phase 1 · 7 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT07390474A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa
Phase 2 · 3 location(s) · International AIDS Vaccine Initiative · NCT05868733A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso.
Phase 1/Phase 2 · 1 location(s) · University of Oxford · NCT05790889Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination
Phase 1/Phase 2 · 1 location(s) · Oregon Health and Science University · NCT05859490A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmaco
Phase 1 · 2 location(s) · Vall d'Hebron Institute of Oncology · NCT07593820Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Phase 3 · 1 location(s) · Shanghai Bovax Biotechnology Co., Ltd. · NCT04422366Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy
Phase 1/Phase 2 · 2 location(s) · University of Melbourne · NCT05187429A Trial of a Next Generation COVID-19 Vaccine Delivered by Inhaled Aerosol
Phase 2 · 2 location(s) · McMaster University · NCT06381739Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination wi
Phase 3 · 2 location(s) · Institute of Tropical Medicine, Belgium · NCT06126822A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）
Phase 1 · 1 location(s) · L & L Bio Co., Ltd., Ningbo, China · NCT05357651A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults
Phase 1/Phase 2 · 1 location(s) · GC Biopharma Corp · NCT06997627Estimate the Safety and Effectiveness of Adjuvanted Influenza Vaccine Among Asian Elderly People When Compared to Non-ad
NA · 1 location(s) · National Taiwan University Hospital · NCT06676644Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With Vaccine Phase III Clinical Trial
Phase 3 · 1 location(s) · Changchun BCHT Biotechnology Co. · NCT07112144Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine
Phase 2 · 1 location(s) · U.S. Army Medical Research and Development Command · NCT03609398A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants
Phase 1 · 1 location(s) · Jade Biosciences, Inc. · NCT07525947A Study to Assess the Safety of ARGX-124 in Healthy Volunteers
Phase 1 · 1 location(s) · argenx · NCT07377396Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors
EARLY_Phase 1 · 1 location(s) · Ruijin Hospital · NCT06577532A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalati
Phase 1 · 6 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT07536308A Phase I Clinical Trial to Assess the Safety and Immunogenicity of DX-104
Phase 1 · 1 location(s) · Shanghai Yuguan Biotech Co., Ltd.（Delonix Bioworks) · NCT07395739Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators
Phase 4 · 1 location(s) · University of Sao Paulo General Hospital · NCT07280741A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idi
Phase 2 · 12 location(s) · Shanghai Synvida Biotechnology Co.,Ltd. · NCT07121413A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
Phase 3 · 54 location(s) · Takeda · NCT06100289A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.
Phase 3 · 5 location(s) · Pfizer · NCT07543380Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad
Phase 1 · 9 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT06665646A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 1 · 11 location(s) · Bambusa Therapeutics · NCT07288554
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.